About Ultivue
Ultivue is a company based in Cambridge (United States) founded in 2015.. Ultivue has raised $105.23 million across 5 funding rounds from investors including Applied Materials, Arch Venture Partners and Ally Bridge Group. Ultivue offers products and services including OmniVUE, U-VUE, InSituPlex, and STARVUE. Ultivue operates in a competitive market with competitors including Personalis, OncoDNA, Strata Oncology, RootPath Genomics and Precede, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ultivue, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$105.23 M (USD)
in 5 rounds
-
Latest Funding Round
$3.32 M (USD), Series D
Jul 11, 2024
-
Investors
Applied Materials
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ultivue
Ultivue offers a comprehensive portfolio of products and services, including OmniVUE, U-VUE, InSituPlex, and STARVUE. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Offers core biomarkers for cancer research analysis
Provides customized biomarker solutions for research needs
Enables ultrasensitive detection of biomarkers in tissues
Delivers AI-enhanced spatial phenomics for tumor microenvironments
Unlock access to complete
Unlock access to complete
Funding Insights of Ultivue
Ultivue has successfully raised a total of $105.23M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $3.32 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series D — $3.3M
-
First Round
First Round
(01 Jun 2015)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series D - Ultivue | Valuation |
investors |
|
| Apr, 2021 | Amount | Series D - Ultivue | Valuation |
investors |
|
| Jun, 2019 | Amount | Series C - Ultivue | Valuation | Northpond Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ultivue
Ultivue has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Applied Materials, Arch Venture Partners and Ally Bridge Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Founded Year | Domain | Location | |
|
Investment management services are provided focusing on healthcare innovation.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ultivue
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ultivue
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ultivue Comparisons
Competitors of Ultivue
Ultivue operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Personalis, OncoDNA, Strata Oncology, RootPath Genomics and Precede, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| domain | founded_year | HQ Location |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| domain | founded_year | HQ Location |
Genetic sequencing is provided for late-stage cancer patients.
|
|
| domain | founded_year | HQ Location |
Immunotherapy platform is developed for personalized cancer treatment.
|
|
| domain | founded_year | HQ Location |
Circulating chromatin is profiled via liquid-biopsy platform for cancer diagnosis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Ultivue
When was Ultivue founded?
Ultivue was founded in 2015.
Where is Ultivue located?
Ultivue is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Ultivue a funded company?
Ultivue is a funded company, having raised a total of $105.23M across 5 funding rounds to date. The company's 1st funding round was a Series C of $26.5M, raised on Jun 01, 2015.
What does Ultivue do?
Ultivue was founded in 2015 and is based in Cambridge, United States, within the biotechnology sector focused on oncology. Biomarker panels are created to assess the immune landscape, supporting precision therapies. Key products include FixVUE, FlexVUE, and U-VUE. Multiplex immunofluorescence services are delivered using proprietary InSituPlex technology, which involves DNA-barcoding and antibody staining for tissue analysis.
Who are the top competitors of Ultivue?
Ultivue's top competitors include Personalis, OncoDNA and ACT Genomics.
What products or services does Ultivue offer?
Ultivue offers OmniVUE, U-VUE, InSituPlex, and STARVUE.
Who are Ultivue's investors?
Ultivue has 9 investors. Key investors include Applied Materials, Arch Venture Partners, Ally Bridge Group, Pura Vida, and Tao Capital Partners.